This video presents compelling patient stories and perspectives shared ahead of the Oncologic Drugs Advisory Committee (ODAC) hearing last September 26, 2024. Patients and survivors of advanced stomach cancer highlight the importance of immunotherapy, even for those who may not meet specific biomarker thresholds like PD-L1. These personal testimonies emphasize the need for flexible treatment options and access to life-saving therapies. Immunotherapy has given hope to those facing limited treatment choices and provides a critical opportunity for survival.
Key points discussed include:
The impact of immunotherapy on patients with advanced gastric cancer
Current challenges with PD-L1 cutoffs and biomarker limitations
Real-life stories of survival and advocacy for broader access to treatment
The video aims to raise awareness and provide context for the ODAC's decision-making process on immunotherapy guidelines and access for gastric cancer patients.

Please consider these patient perspectives in the upcoming hearing to ensure more lives can be saved through flexible treatment options.

свернуть